RYTM RHYTHM PHARMACEUTICALS, INC.: institutional ownership and insider trading
318 funds reported holding $9.34B of RHYTHM PHARMACEUTICALS, INC. in their latest 13F filings; in Q2 2026 funds net bought $412M, with 60 new positions and 41 funds selling out; over the last 12 months insiders bought $0 and sold $40.1M on the open market.
Famous investors holding RYTM
- Stanley Druckenmiller (Duquesne Family Office): $22.6M, 0.4% of the portfolio
- Ken Griffin (Citadel Advisors): $145M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $35.2M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $7.58M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $3.35M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $511K, 0.0% of the portfolio
Largest institutional holders of RYTM
- RA CAPITAL MANAGEMENT, L.P. — $740M
- BlackRock, Inc. (BLK) — $684M
- VANGUARD GROUP INC — $665M
- BAKER BROS. ADVISORS LP — $622M
- PRIMECAP MANAGEMENT CO/CA/ — $352M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $348M
- VANGUARD CAPITAL MANAGEMENT LLC — $334M
- JPMORGAN CHASE & CO (JPM, AMJB, VYLD, JPM-PC, JPM-PD, JPM-PJ, JPM-PK, JPM-PL, JPM-PM) — $292M
- PERCEPTIVE ADVISORS LLC — $287M
- STATE STREET CORP (STT, STT-PG) — $286M
Recent RYTM insider trades
- Sep 14, 2026: Meeker David P sold 50,000 shares ($5.13M)
- Aug 31, 2026: Smith Hunter C sold 62,774 shares ($6.62M)
- Aug 13, 2026: Garfield Alastair sold 7,763 shares ($913K)
- Aug 13, 2026: Shulman Joseph sold 5,079 shares ($608K)
5%+ owners
- JPMORGAN CHASE & CO.: 5.1% (Schedule 13G, filed Oct 13, 2026)
- Perceptive Advisors LLC: 5.1% (Schedule 13G/A, filed May 15, 2026)
- Vanguard Capital Management: 5.0% (Schedule 13G, filed Apr 30, 2026)